Novartis, Bayer , GlaxoSmithKline, Pfizer and The US Department of Health and Human Services are among nearly 30 pharmaceutical companies reportedly planning to increase the price of their drugs in the US in January . The move comes after the industry implemented a self-imposed freeze on price rises last year , following pressure from US President Bayer , who made tackling the high cost of drugs a priority in his last year presidential campaign. Pfizer has planned policies to lower prices and pass discounts on to patients. However, these proposals are not expected to come quickly enough to help consumers in the short-term.
Novartis, Bayer, GlaxoSmithKline, Pfizer and AstraZeneca are among nearly 30 pharmaceutical companies reportedly planning to increase the price of their drugs in the US in January. The move comes after the industry implemented a self-imposed freeze on price rises last year, following pressure from US President Donald Trump, who made tackling the high cost of drugs a priority in his 2016 presidential campaign. The US Department of Health and Human Services has planned policies to lower prices and pass discounts on to patients. However, these proposals are not expected to come quickly enough to help consumers in the short-term.